The Nebraska Stroke Center and the University of Nebraska Medical Center engage in clinical research with the goal of providing the most advanced care available, while seeking to further our understanding of stroke path physiology and management. Patients are only enrolled in clinical trials after informed consent has been obtained. The goal of the study, risks, benefits, and other treatment options are explained in detail to potential patients.
IRIS: Insulin Resistance Intervention after Stroke
The University of Nebraska Medical Center is seeking patients who have suffered a stroke or a particular transient ischemic attack (TIA) to participate in a clinical trial.
For survivors of ischemic stroke a major source of subsequent mortality and functional decline is recurrent stroke and heart attack. On average, within five years of the initial event, 25 percent of patients who survive an initial stroke will have a recurrent stroke, 10 percent will have a heart attack and 12 percent will die from one of these conditions. Prevention of recurrent stroke and other vascular events, therefore, is of major importance.
The IRIS trial will examine a new therapeutic approach that is based on the detection and treatment of insulin resistance. Insulin resistance affects almost all patients with type 2 diabetes and 50 percent of non-diabetic patients with ischemic stroke. Based on past research, investigators think that treatment of insulin resistance may reduce the incidence of stroke and heart attack. This is an international NIH-funded study.
To test this hypothesis the IRIS trial will determine the effectiveness of pioglitazone, an agent that reduces insulin resistance, for reducing the risk for stroke or heart attack among patients with a recent ischemic stroke. Participants must be age 45 or older and must have had a stroke no less than 14 days ago and no more than 6 months before randomization. Participants must also meet the criteria for insulin resistance and cannot currently be on a diabetic medication regimen.
Mary Phillips, Research Nurse Coordinator
University of Nebraska Medical Center, Clinical Research Center
CHOICE: Carotid Stenting for High Risk Patients; Evaluating Outcomes Through The Collection of Clinical Evidence
The CHOICE study is a prospective, non-randomized, descriptive, multi-center study that will provide additional information that the commercially available Abbott Vascular Carotid Stent Systems and Embolic Protection Systems can be used successfully by a wide range of physicians under commercial use conditions.
Study inclusion criteria include:
Patients who are considered to be high risk for carotid endarterectomy (CEA) and require percutaneous carotid angioplasty and stenting for carotid artery disease; And patient’s physician intends to use and RX Acculink with the RX Accunet or an Xact with the Emboshield in the carotid artery per approved FDA indications.
For questions contact:
Karen Taylor, Research Nurse Coordinator University of Nebraska Medical Center, Department of Surgery phone: 402-559-3935
Augmented Sensory Feedback in Motor Learning in Chronic Stroke Survivors
The University of Nebraska Medical Center is participating in a research study to determine whether chronic stroke subjects can make more accurate reaching movements after training reaching movements with augmented visual feedback.
The benefits of this study include: Furthering the understanding of control of movements in stroke subjects, utilizing a new technology for learning impaired movements and providing a new direction to stroke rehabilitation.
Participants must be 50 to 70 years of age, stroke onset within 5 years, unilateral stroke, single stoke episode and ability to follow a three-step command.
For more information please contact:
Pierre Fayad, MD
Reynolds Centennial Professor & Chairman
Department of Neurological Sciences
University of Nebraska Medical Center